[How long does it take to steam fish in a microwave oven]_Steamed fish_Production time_How long does it take

Microwave steaming fish is a popular method for making fish. It is not only used when it is used, but also does not lose the nutritional value of the fish, so it is very popular.

But in life, there are still many people who do n’t know how long it takes to cook fish in a microwave oven. In fact, it takes about 6-8 minutes to steam fish in a microwave oven. The timing must not be too long.

So what is the practice of steaming fish in a microwave oven?

First, 1 fish, 1 tbsp of cooking wine, 2 segments of spring onion, 2 slices of ginger, 10 g of cooking oil.

Second, practice 1.

Clean up the fish and dry the water.

2.

Before making it, make three strokes on each side of the fish body, and then connect the meat on the edge of the blade. Salt the inside of the fish belly and the head of the fish without using too much.

3.

Then pour a little cooking wine on the fish, so that the whole fish can be stained.

4.

Prepare a little spring onion, cut it into small spring onions, and set aside.

5,

Then cut a few ginger slices (thin ones are fine), clip them to the knife, each clip is OK, cut a little ginger, put in the fish belly and fish head, and finally sprinkle a little ginger on the fish,It’s almost the same.

After the above steps are completed, put on cling film (without pickling), pierce a few holes, and put them in the oven. The fish can be cooked for 6 minutes on high heat. The fish is tender.

6.

After the fish is steamed, remove it, tear off the plastic wrap, and sprinkle with green onions.

7.

Pour two small tablespoons of raw soy sauce onto the fish.

8.

Take another small bowl and put a little oil into the microwave oven and heat it for 45 seconds on high heat, or heat it in a wok and pour it on the fish.

Third, the nutritional value of scallion, green onion, spicy, slightly warm, has the effect of publishing Tongyang, detoxification and flavoring.

It is mainly used for colds, colds, fever, headache, nasal congestion, cold and abdominal pain, sudden diarrhea, internal resistance of worms, impaired milk, and unfavorable conditions.

Welsh shallot contains volatile oil. The main ingredient in the oil is allicin, and it also contains diene endyl sulfide and calcium oxalate.

In addition, it also contains trace amounts, sugars, carotene, etc., vitamins B, C, nicotinic acid, calcium, magnesium, and iron.

1.

Raw onions, like onions and green onions, contain allyl sulfide.

Allyl sulfide can stimulate the secretion of gastric juice and help increase appetite.

At the same time when ingested with foods with vitamin B1 content, the starch and sugars contained in vitamin B1 will be transformed, which will improve the effect of restoring fatigue.

2.

The green onion leaves contain more vitamin A, vitamin C and calcium than the white onions.

Onion contains a considerable amount of vitamin C, which relaxes small blood vessels and promotes blood circulation. It helps prevent dizziness caused by increased blood pressure, keeps the brain flexible, and prevents dementia.

3.

People who regularly eat shallots, even if they are fat and fat, their plasma does not increase and their physique is strong.

The spring onion is rich in trace element selenium, which reduces the content of nitrite in gastric juice, and has certain effects on preventing gastric cancer and various cancers.

4.

Green onion green has irritating volatile oils and spicy ingredients, which can eliminate the odor caused by greasy thick tastes such as fishy fish, produce special aroma, and have an alternative bactericidal effect, which can stimulate the secretion of digestive juice and promote appetite.

Volatile spicy hormones can also slightly stimulate the secretion of related glands when excreted through sweat glands, respiratory tract, and urinary system, and cause sweating, expectorant, and diuretic effects.
Is one of the traditional Chinese medicine for colds.

Zingiberaceae, Zingiberaceae, also known as “ginger”; rhizomes with yellow-green flowers and pungent scent.
Fresh or dried rhizomes can be used as condiments.

Ginger is one of the medicinal materials for traditional Chinese medicine after being processed.

1 Ginger also has the effect of detoxifying and sterilizing. When we eat aquatic products such as pine eggs or fish and crabs, we usually put some ground ginger and ginger juice.

After gingerol in ginger enters the body, it can produce an antioxidant enzyme, which has a strong ability to deal with oxygen free radicals, and is much stronger than vitamin E.

2 Teenagers eat ginger can be beauty, girls eat ginger can make the complexion look rosy and full of youthful charm!

3Ginger extract can stimulate gastric mucosa, cause reflex excitement of vascular motor centers and sympathetic nerves, promote blood circulation, stimulate gastric function, and achieve the effects of stomach strengthening, analgesia, sweating, and antipyretics.

Ginger’s volatile oil can enhance the secretion of gastric juice and the peristalsis of the intestinal wall, thereby helping digestion.

4 The mixture of gingerene and gingerone isolated from ginger has obvious antiemetic effect.

5Ginger extract has the effects of significantly inhibiting skin wrinkles and killing trichomoniasis, and can treat various edema and sore poisons.

Spring Airlines (601021): Adhering to the strategic strategy, the benefits are continuously optimized

Civil aviation supply-side reforms continue to materialize, and combined with the impact of the 737MAX air crash and the civil aviation development fund halved, the industry boom has risen, driving both performance and valuation to rise.

We conservatively forecast Spring Airlines’ EPS of 2 in 19/20/21.

09/2.

35/2.

53 yuan, corresponding to the current expectation of 20.

0/17.

8/16.

5x PE; The company insists on revenue optimization and cost control, with both growth and price increase expectations. It gives a target price of 48 yuan and maintains a “strong recommendation-A” rating.

The company announced the 2018 annual report, which was slightly higher than expected.

Spring Airlines disclosed the 2018 annual report and effectively realized revenue of 151.

$ 3.4 billion, + 20% per year; net profit attributable to mother 15 was achieved.

03 trillion, + 19% a year; basic EPS is 1.

64 years +0.

06; expected ROE is 11.

3%, at least -3.

6 points.

Expansion of Asian route layout, international ASK growth rate reached 20.

25%.

The 18-year company ASK was 389.

700 million person-kilometers, +16 per year.

66%, of which domestic +14.

85%, international +20.

25%.

Subject to civil aviation supply-side reforms, in 18 years when domestic first- and second-tier airports were newly added, the ASK growth rate improved; benefiting from the expansion of the three main routes in Thailand, Japan, and South Korea, at least +22.

1%, international ASK has grown rapidly.

Revenue optimization policies have been significantly improved, and cost control capabilities have continued to improve.

In 18 years, the company continued to improve its revenue management policy, and its initial passenger-km revenue was zero.

37 yuan, previously + 6%, but load factor decreased by 1.

55 points to 89.

01%, the potential to improve profitability.

As future fiscal reforms continue to advance, there is still room for improvement in domestic seat revenue.

In terms of cost, 18 years have been dragged down by the price of jet fuel and the unit operating cost was zero.

3 yuan, +5 per year.

3%; after deducting the influence of jet fuel, the cost control level is still excellent, and the unit non-oil cost is zero.

201 yuan, -1 a year.

3%, mainly due to the increase of the aircraft’s daily available hours (a total of 2% increase in 18 years, effectively reducing the fixed cost).

In the future, the concentration of base routes will be enhanced, and an international development strategy will be adhered to.

Under the policy of China Civil Aviation’s control scale and structural adjustment, the company is expected to increase the concentration of base routes in 19 years, and new moments in the first and second-tier markets are expected to bring about marginal improvement.The company adheres to the international development strategy. In 19 years, it will continue to strengthen the supply capacity of Japan, South Korea, and Thailand and improve the comprehensive income level. It is expected that the capacity growth of Northeast Asia will exceed that of Southeast Asia.

Catalysts: 1) Affected by the 737 largest air crash, the civil aviation capacity supply and transportation in 19-20 years, it is expected that the difference between supply and demand growth in the second half of 19 will increase to 3%.

At present, the company does not have a 737MAX budget, and its capacity is reduced. However, through the arrival of the peak season, civil aviation alternatives are sought, and the company will benefit from increased revenue.

2) The plan for halving the levy of the Civil Aviation Development Fund was passed, and the company’s pre-tax profit is expected to increase by 1%.

400 million yuan.

Risk warning: sharp rise in oil prices, sharp depreciation of the 重庆耍耍网 RMB, etc.

Livzon Group (000513) Annual Report 2018 Review: Improved Revenue Structure and R & D Layout Accelerate

The performance growth was stable, basically in line with expectations of the company’s operating income in 201888.

6.1 billion (+3.

86%), net profit attributable to mother 10.

8.2 billion (-75.

56%), mainly due to the increase in the company’s equity transfer in Zhuhai Weixing Industrial in 2017 to return the net profit of the mother 32.

8.4 billion, net profit attributable to mothers after eliminating non-recurring gains and losses.

4.7 billion (+15.

51%), and performance was basically in line with expectations.

In 2018, the company achieved a net operating cash flow of 12.

6.8 billion, with good financial condition.

　　Innovative products maintained high growth, and the revenue structure improved rapidly.

6.1 billion (+40.

34%), ilaprazole 5.

8.8 billion (+37.

35%) and rabeprazole 2.

2.7 billion (+40.

53%) and other major varieties maintained high growth, the company’s revenue share increased rapidly, and the revenue ratio of the three products reached 17.

79%.

Shenqi Fuzheng injection 10.

02 billion (-36.

31%), rat nerve growth factor 4.

4.4 billion (-14.

(09%), due to the appropriate clinical use, bidding price reduction and other factors, the proportion of the company’s operating income rapidly decreased, two pressure products accounted for the company’s operating income in 2018 of 16

32%, is expected to continue to drop to 11 in 2019.

About 5%.

High-end products in the field of assisted reproduction and digestive tract have become the main force to promote the growth of the company’s performance, 厦门夜网 and pressure-bearing products have alleviated the drag on performance.

　　The R & D investment continued to be high, and the layout of products under development accelerated the company’s R & D investment in 20186.

8.7 billion (+19.

42%), accounting for 7 of operating income.

76%, an increase of 1 over the previous year.

01pp.

Considering that the company’s microspheres, monoclonal antibodies, and precision medical multiple R & D platforms are carried out simultaneously, we expect that the R & D intensity in 2019 will further increase.

At present, recombinant human chorionic gonadotropin, leuprolide microspheres (3 months sustained release) have been declared for production, Her2 monoclonal antibody has completed Phase 1 clinical trials, and PD-1 monoclonal antibody has entered the final phase of Phase 1 clinical trials 杭州养生会所 in China and the United States, And started clinical trials of combined chemotherapy in China. The CAR-T project has completed the establishment of a technology platform and has completed the development of multiple targets.

Lizhu Gene’s non-invasive and accurate inspection product “Li Fei Qing” lung nodules benign and malignant identification test was officially released.

　　Risk warning: Shenqi Fuzheng, risk of bidding for rat nerve growth factor price reduction; the progress of research and development of innovative products is less than expected; the market promotion of products is less than expected.

　　Investment suggestion: target price 41.

0?

45.
1 yuan, maintain “Buy” rating.
　　The company’s EPS for 2019-2021 is expected to be 1.

74/2.

05/2.

36 yuan, the current sustainable corresponding PE is 20.

7/17.

6/15.

2 times.

The company’s innovative products maintain high growth, the product revenue structure is rapidly improving, the R & D continues to be high, the precision medicine layout is perfect, the transition period has sufficient capital reserves, and there is an outbound M & A expectation. A reasonable estimate of 20-22x is given in 2020, corresponding to a target price of 41.

0?45.

1 yuan, maintain “Buy” rating.